Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection

Camarero, Judith Gómez; Aranda, Ester Badia; Castro, Raisa Quiñones; Chumillas, Rosa María Saiz; Vega, Laura; Ruiz, Sandra Díez; Manero, Noemí Gómez; Campo, Raquel Vinuesa; Plaza, Francisco Jorquera

doi:10.1016/j.gastre.2022.04.003

Cited by 2 publications

(3 citation statements)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8][9][10][11] In rare instances, COVID-19 infection without immunosuppressive treatment may lead to reactivation of hepatitis B and liver failure, such as in our case. 12,13 It is not yet fully understood how COVID-19 infection, without using an immunosuppressant, directly affects the pathophysiology of HBVr because of a lack of data. Reportedly, 33%-96% of patients with COVID-19 experience lymphopenia, which could potentially lead to an increase in viral load and ultimately cause HBVr.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection

Mushtaq,

Colletier,

Moghe

2024

ACG Case Rep J

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been associated with liver injury incidence reported between 15% and 53%. Viral binding to ACE2 receptors in hepatobiliary cells is believed to cause liver inflammation. The relationship between hepatitis B and COVID-19 is poorly understood, but patients treated with immunosuppressive therapy for COVID-19 are at higher risk of hepatitis B reactivation (HBVr). We present a case of a patient with HBVr because of COVID-19, in the absence of any immunosuppressive treatment, leading to fulminant liver failure and subsequent requiring liver transplantation. Given low incidence, limited data, and no current guidelines, further studies are needed to evaluate the benefit and cost-effectiveness of anti-HBV prophylaxis in a patient with chronic hepatitis B (CHB) and COVID-19. Meanwhile, the American Association for the Study of Liver Diseases guidelines for patients with CHB and immunosuppressant use can be considered for anti-HBV prophylaxis for patients with CHB and COVID-19 to prevent HBVr on a case-by-case basis.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection

Mushtaq,

Colletier,

Moghe

2024

ACG Case Rep J

View full text Add to dashboard Cite

show abstract

“…The results of this cross-sectional study showed HBV reactivation in 14.2% of patients who did not use entecavir prophylaxis during treatment with immunosuppressants. 17 A prospective cohort, with the aim of establishing the risk of hepatitis B virus reactivation in COVID-19 patients, showed in its results that 87% of co-infected patients had high ALT levels. Most of the patients who required immunomodulatory therapy, tocilizumab being the main medication, received prophylaxis with entecavir.…”

Section: Discussionmentioning

confidence: 99%

“…16 Evaluates the results of a screening program for hepatitis B and C in hospitalized patients with COVID-19. 17 Scenario of viral hepatitis in the COVID-19 pandemic in Africa, consequences and recommendations. 18 The author's opinion on the outcomes of hepatitis B and COVID-19 infections.…”

Section: Thematic Considerationsmentioning

confidence: 99%

Evidências científicas sobre hepatite B e infecção por SARS-CoV-2: revisão integrativa

Oliveira,

Costa,

Silva

2023

Rev Epidemiol Control Infect

View full text Add to dashboard Cite

Justificativa e Objetivos: a hepatite B é uma doença infectocontagiosa provocada por um vírus da família hepadnaviridae, com distribuição mundial, e representa um grave problema de saúde global. A patologia pode ter sido afetada pela pandemia de COVID-19, provocada pelo vírus SARS-CoV-2, sendo possível a ocorrência de desfechos graves na sobreposição entre os dos tipos virais. Este estudo buscou descrever os níveis de evidências científicas de pesquisas realizadas sobre o tema, estabelecendo relação entre a infecção por vírus da hepatite B e a infecção por SARS-CoV-2. Conteúdo: revisão integrativa da literatura, com buscas realizadas nas bases de dados do Medical Literature Analysis and Retrieval System Online e Scientific Electronic Library Online, com análise centrada na descrição do delineamento metodológico e na classificação do nível de evidência. Conclusão: a produção científica sobre hepatite B associada a infecção por SARS-CoV-2 corresponde majoritariamente a pesquisas com baixo nível de evidência. As publicações selecionadas apresentaram limitações, como a ocorrência de estudos com número reduzido de amostras, falta de dados subsidiários de pacientes em tratamento e ocorrência de seleção não randomizada. Os resultados sugerem a necessidade de novas investigações para fins de incrementos tecnológicos, identificação de fatores de risco, intervenção terapêutica e investigação clínica avançada, de forma a fomentar práticas assistenciais em saúde baseadas em evidências.

show abstract

Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection

Cited by 2 publications

References 14 publications

Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection

Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection

Evidências científicas sobre hepatite B e infecção por SARS-CoV-2: revisão integrativa

Contact Info

Product

Resources

About